What we do Hester Biosciences Ltd is a leading Indian company specializing in manufacturing and trading of poultry and large animal vaccines, health products, pharmaceuticals, and diagnostics. |
Founded in 1,987 |
Market share A pioneer in animal healthcare in India with growing presence in Africa and Asia, holding a strong market position in veterinary vaccines and health products. |
Problem solved Provides reliable vaccines and health products to prevent and control animal diseases, supporting poultry and livestock health management globally. |
Top clients or who we serve B2B customers including poultry farms, veterinary clinics, livestock farmers across India, Africa, Nepal, Bangladesh, and Southeast Asia. |
Key management Rajiv Gandhi (CEO & Managing Director), Priya Gandhi (Executive Director), Divyesh Maru (Chief Financial Officer) |
Our journey and innovations Started in 1987; expanded vaccine portfolio; global expansion with subsidiaries in Nepal, Africa, Kenya, Tanzania; launched pet care division and new vaccines recently. |
Where we operate India, Nepal, Tanzania, Kenya, various African countries, Vietnam, Indonesia, Bangladesh |
Top products or what we offer Over 51 vaccines for poultry and large animals, 70+ health products, pharmaceuticals, feed supplements, disinfectants, pet care products. |
Top brands LIVACOX (exclusive distributor for coccidiosis vaccine), bivalent Marek's Disease vaccine, various poultry and large animal vaccines and supplements. |
Raw materials needed Biological materials for vaccines, pharmaceutical ingredients, feed supplement components |
Raw materials supplier International partners like Ghen Corporation (Japan), Maine Biological Laboratories (US), Biogal Galed Laboratories (Israel), Kemin Europa (Belgium) |
Recurring vs cyclical contribution Revenue largely recurring through continuous demand for vaccines and health products in animal husbandry. |
Our industry position Market leader in Indian veterinary vaccines with expanding international footprint and strong partnerships for global distribution. |
Financial highlights Consolidated Revenue INR 311.1 Cr, Net Profit INR 27.49 Cr for FY2024-25, steady growth in revenue and profitability year-over-year. |
Geographical revenue split India accounts for approximately 83.7% revenue (INR 260.95 Cr), international markets 16.3% (INR 50.15 Cr) as of FY2024-25. |
Order book - |
Whats driving growth Product innovation, capacity expansion, international subsidiaries, increasing demand for animal healthcare and petcare products. |
Our future plans Expand vaccine production capacity, strengthen international manufacturing and distribution, launch new animal health and pet care products. |
Our green promise Committed to sustainability with ISO 14001 environmental management certification and responsible manufacturing practices. |
Our people and values Focus on ethical practice, employee welfare, diversity, and continuous development fostering a skilled workforce. |
Key challenges ahead Regulatory compliance, market competition, managing supply chain and raw material dependencies, expanding global market share. |
Interesting facts First Indian company with licenses for 10 new poultry vaccines, exclusive distributor for BIOPHARM's LIVACOX vaccine in India. |
Risks and strategy Mitigates risks by diversifying product portfolio, building strong partnerships, and investing in R&D and quality standards. |
